An exploratory, randomised, active-controlled, double-blind, double-dummy, parallel group pilot study to determine the ability of oxycodone/naloxone prolonged release tablets (OXN) to reduce the number of subjects developing symptoms of opioid induced constipation compared to morphine prolonged release tablets (MOR PR) in opioid naive, non-constipated subjects with non malignant pain that require opioid treatment.

Trial Profile

An exploratory, randomised, active-controlled, double-blind, double-dummy, parallel group pilot study to determine the ability of oxycodone/naloxone prolonged release tablets (OXN) to reduce the number of subjects developing symptoms of opioid induced constipation compared to morphine prolonged release tablets (MOR PR) in opioid naive, non-constipated subjects with non malignant pain that require opioid treatment.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2012

At a glance

  • Drugs Morphine; Oxycodone/naloxone
  • Indications Constipation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mundipharma GmbH
  • Most Recent Events

    • 20 Jun 2012 Actual initiation date changed from 30 Mar 2009 to 22 May 2008 as reported by European Clinical Trials Database.
    • 20 Jun 2012 Planned end date changed from 30 Sep 2010 to 22 Nov 2009 as reported by European Clinical Trials Database.
    • 24 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top